Cargando…

5-HT(2C) Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators

Obesity is a substantial health and economic issue, and serotonin (5-hydroxytryptamine, 5-HT) is an important neurotransmitter system involved in the regulation of body weight. The 5-HT(2C) receptors (5-HT(2C)Rs), one of 16 of the 5-HT receptor (5-HTRs) subtypes, play a significant role in food inta...

Descripción completa

Detalles Bibliográficos
Autores principales: Przegaliński, Edmund, Witek, Kacper, Wydra, Karolina, Kotlińska, Jolanta H., Filip, Małgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058696/
https://www.ncbi.nlm.nih.gov/pubmed/36986191
http://dx.doi.org/10.3390/nu15061449
_version_ 1785016695785521152
author Przegaliński, Edmund
Witek, Kacper
Wydra, Karolina
Kotlińska, Jolanta H.
Filip, Małgorzata
author_facet Przegaliński, Edmund
Witek, Kacper
Wydra, Karolina
Kotlińska, Jolanta H.
Filip, Małgorzata
author_sort Przegaliński, Edmund
collection PubMed
description Obesity is a substantial health and economic issue, and serotonin (5-hydroxytryptamine, 5-HT) is an important neurotransmitter system involved in the regulation of body weight. The 5-HT(2C) receptors (5-HT(2C)Rs), one of 16 of the 5-HT receptor (5-HTRs) subtypes, play a significant role in food intake and body weight control. In this review, we focused on the 5-HTR agonists, such as fenfluramines, sibutramine, and lorcaserin, which act directly or indirectly at 5-HT(2C)Rs and have been introduced into the clinic as antiobesity medications. Due to their unwanted effects, they were withdrawn from the market. The 5-HT(2C)R positive allosteric modulators (PAMs) can be potentially safer active drugs than 5-HT(2C)R agonists. However, more in vivo validation of PAMs is required to fully determine if these drugs will be effective in obesity prevention and antiobesity pharmacology treatment. Methodology strategy: This review focuses on the role of 5-HT(2C)R agonism in obesity treatment, such as food intake regulation and weight gain. The literature was reviewed according to the review topic. We searched the PubMed and Scopus databases and Multidisciplinary Digital Publishing Institute open-access scientific journals using the following keyword search strategy depending on the chapter phrases: (1) “5-HT(2C) receptor” AND “food intake”, and (2) “5-HT(2C) receptor” AND “obesity” AND “respective agonists”, and (3) “5-HT(2C) receptor” AND “PAM”. We included preclinical studies (only present the weight loss effects) and double-blind, placebo-controlled, randomized clinical trials published since the 1975s (mostly related to antiobesity treatment), and excluded the pay-walled articles. After the search process, the authors selected, carefully screened, and reviewed appropriate papers. In total, 136 articles were included in this review.
format Online
Article
Text
id pubmed-10058696
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100586962023-03-30 5-HT(2C) Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators Przegaliński, Edmund Witek, Kacper Wydra, Karolina Kotlińska, Jolanta H. Filip, Małgorzata Nutrients Review Obesity is a substantial health and economic issue, and serotonin (5-hydroxytryptamine, 5-HT) is an important neurotransmitter system involved in the regulation of body weight. The 5-HT(2C) receptors (5-HT(2C)Rs), one of 16 of the 5-HT receptor (5-HTRs) subtypes, play a significant role in food intake and body weight control. In this review, we focused on the 5-HTR agonists, such as fenfluramines, sibutramine, and lorcaserin, which act directly or indirectly at 5-HT(2C)Rs and have been introduced into the clinic as antiobesity medications. Due to their unwanted effects, they were withdrawn from the market. The 5-HT(2C)R positive allosteric modulators (PAMs) can be potentially safer active drugs than 5-HT(2C)R agonists. However, more in vivo validation of PAMs is required to fully determine if these drugs will be effective in obesity prevention and antiobesity pharmacology treatment. Methodology strategy: This review focuses on the role of 5-HT(2C)R agonism in obesity treatment, such as food intake regulation and weight gain. The literature was reviewed according to the review topic. We searched the PubMed and Scopus databases and Multidisciplinary Digital Publishing Institute open-access scientific journals using the following keyword search strategy depending on the chapter phrases: (1) “5-HT(2C) receptor” AND “food intake”, and (2) “5-HT(2C) receptor” AND “obesity” AND “respective agonists”, and (3) “5-HT(2C) receptor” AND “PAM”. We included preclinical studies (only present the weight loss effects) and double-blind, placebo-controlled, randomized clinical trials published since the 1975s (mostly related to antiobesity treatment), and excluded the pay-walled articles. After the search process, the authors selected, carefully screened, and reviewed appropriate papers. In total, 136 articles were included in this review. MDPI 2023-03-17 /pmc/articles/PMC10058696/ /pubmed/36986191 http://dx.doi.org/10.3390/nu15061449 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Przegaliński, Edmund
Witek, Kacper
Wydra, Karolina
Kotlińska, Jolanta H.
Filip, Małgorzata
5-HT(2C) Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators
title 5-HT(2C) Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators
title_full 5-HT(2C) Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators
title_fullStr 5-HT(2C) Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators
title_full_unstemmed 5-HT(2C) Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators
title_short 5-HT(2C) Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators
title_sort 5-ht(2c) receptor stimulation in obesity treatment: orthosteric agonists vs. allosteric modulators
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058696/
https://www.ncbi.nlm.nih.gov/pubmed/36986191
http://dx.doi.org/10.3390/nu15061449
work_keys_str_mv AT przegalinskiedmund 5ht2creceptorstimulationinobesitytreatmentorthostericagonistsvsallostericmodulators
AT witekkacper 5ht2creceptorstimulationinobesitytreatmentorthostericagonistsvsallostericmodulators
AT wydrakarolina 5ht2creceptorstimulationinobesitytreatmentorthostericagonistsvsallostericmodulators
AT kotlinskajolantah 5ht2creceptorstimulationinobesitytreatmentorthostericagonistsvsallostericmodulators
AT filipmałgorzata 5ht2creceptorstimulationinobesitytreatmentorthostericagonistsvsallostericmodulators